News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Stock Titan Guidance
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Gentherm Inc. (THRM) has filed a notice under Rule 144 to sell up to 4,700 shares of its common stock through Merrill Lynch on NASDAQ, with a noted transaction date of July 29, 2026. The filing also details prior stock plan activities, including share …
Gentherm (NASDAQ: THRM) reported increased product revenues of $416.166 million in Q2 2026, up from $375.090 million a year earlier, with net income rising to $4.420 million. The company is advancing its $1 billion Reverse Morris Trust merger with Modine’s Performance Technologies business, expected …
This page provides live quotes and charts for Gentherm Inc (THRM) stock, showing its current trading price and recent performance. It also includes sections for analyst ratings and earnings information, although data for these sections is currently unavailable. The article is part of a …
This page provides a comprehensive overview of Gentherm's (THRM) SEC filings, including annual, quarterly, and material event reports, as well as insider trading forms. It features AI-generated summaries, impact scoring, and sentiment analysis for each filing. Recent filings highlight passive investment disclosures, a new …
Gentherm (NASDAQ: THRM) has acquired Innovative Medical Equipment, LLC (IME), a Cleveland-area provider of the ThermaZone thermal therapy device. This acquisition is a strategic move to strengthen Gentherm's Medical business and expand its product portfolio, although the financial terms of the transaction were not …
Gentherm Inc. (THRM) shares surged over 26% due to several converging catalysts, including FDA 510(k) clearance for its ThermAffyx Patient Safety System and the acquisition of Innovative Medical Equipment. Analysts from Stifel and JPMorgan subsequently raised their price targets, indicating bullish sentiment on Gentherm's …
Gentherm reported strong second-quarter 2026 results, with product revenues up 11.0% year over year and adjusted diluted EPS increasing to $0.75. The company raised its full-year 2026 guidance for product revenues, adjusted EBITDA, and adjusted free cash flow, reflecting confidence in its performance. Additionally, …
Bessemer Group Inc. significantly increased its stake in Gentherm Inc. (NASDAQ:THRM) during the first quarter by 50.5%, acquiring an additional 43,500 shares. The auto parts company also reported strong first-quarter earnings, beating analyst estimates for both EPS and revenue, with revenue rising 11.2% year-over-year. …
Gentherm Inc. has received FDA 510(k) clearance for its ThermAffyx™ Patient Safety System, a Class II medical device designed for patient warming and securement during robotic-assisted surgeries. This innovative system aims to address challenges such as hypothermia and patient movement, especially in the Trendelenburg …
Gentherm received FDA 510(k) clearance for its ThermAffyx Patient Safety System, a Class II medical device designed for robotic-assisted surgeries. This innovative system combines active patient warming, securement, and pressure reduction, addressing critical safety gaps in millions of procedures annually. Product trials are set …
Gentherm (THRM) announced FDA 510(k) clearance for its ThermAffyx™ Patient Safety System, a Class II medical device designed for robotic-assisted surgeries. This innovative system integrates active underbody warming, securement, and pressure reduction, addressing the challenges of patient hypothermia in procedures like the Trendelenburg position. …
Search by ticker symbol or company name and select a result to open its chart.